Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from PolyPeptide Group AG ( (CH:PPGN) ) is now available.
PolyPeptide Group AG has announced the agenda for its fourth ordinary General Meeting in April 2025, where key board members will stand for re-election, and a new independent member, Jo LeCouilliard, is proposed for election. The meeting will also address the introduction of authorized and conditional share capital to enhance financial and strategic flexibility, alongside other standard agenda items such as re-election of auditors and approval of financial statements.
More about PolyPeptide Group AG
PolyPeptide Group AG is a specialized contract developer and manufacturer for peptide- and oligonucleotide-based active pharmaceutical ingredients, primarily serving the Pharma and Biotech sectors. The company operates a global network of six GMP-certified production facilities and focuses on drug therapies for metabolic diseases, including GLP-1.
YTD Price Performance: -35.77%
Average Trading Volume: 56,243
Technical Sentiment Consensus Rating: Buy
Current Market Cap: CHF613.1M
Learn more about PPGN stock on TipRanks’ Stock Analysis page.